Search company, investor...

Predict your next investment

Venture Capital
elaia.com

Investments

158

Portfolio Exits

33

Funds

5

Partners & Customers

1

Service Providers

1

About Elaia Partners

Elaia Partners is a European VC firm focusing in digital and deep tech and early-stage ventures.

Headquarters Location

54 Rue de Ponthieu

Paris, 75008,

France

+33 1 76 74 92 50

Want to inform investors similar to Elaia Partners about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Research containing Elaia Partners

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Elaia Partners in 1 CB Insights research brief, most recently on Sep 24, 2021.

Latest Elaia Partners News

Mablink Bioscience secures €31M to develop better treatment for cancer patients

Oct 17, 2022

Mablink Bioscience (Mablink), a Lyon-based biotechnology company, has raised €31M in a Series A funding round led by Sofinnova Partners and Mérieux Equity Partners, with participation from existing investors. Existing shareholders, Elaia Partners, UI-Investissement / Pertinence Invest 2 (advised by Mérieux Equity Partners), Sham Innovation Santé (advised by Turenne Capital), Fondation Fournier-Majoie, Simba Santé (Angelor) and Crédit Agricole Création also participated in the funding round. The capital will allow Mablink to become clinical-stage biotech by bringing its lead candidate, MBK-103, into clinical development to treat solid tumors, notably ovarian cancer. At the same time, Mablink will build a pipeline of ADCs for solid tumors. As part of the funding round, Dr. Calenda and Mr. Seghezzi join Mablink’s Board of Directors. “We are very proud to be joined by such experienced investors,” says Jean-Guillaume Lafay, Chief Executive Officer and co-founder of Mablink. “They bring the necessary funds but also the expertise and network that will be critical for the success of Mablink in bringing its first ADC to the clinic. We also thank our historical investors who decided to reinvest in this round.” Developing antibody-drug conjugates Mablink’s technology is based on a unique structure of chemical links (called “linkers”) placed between an antibody and any chosen cytotoxic molecule to be delivered into tumor cells. The linkers mask the cytotoxic molecule, which provides a “stealthy” property to Mablink’s ADCs, conferring two highly desirable pharmacological properties. First, it enables ADCs to stay longer in the body and gives them more time to destroy tumor cells. Second, these stealth ADCs have greatly improved tolerability. Consequently, it results in a 10-fold increase in the therapeutic index observed in animal models, a potentially game-changing factor for future clinical successes in the ADC space. “Mablink offers a complete solution that tackles the challenges currently limiting the development of ADCs,” says Graziano Seghezzi, Managing Partner at Sofinnova Partners. “With its “masking” technology, we have the potential to build a pipeline of products for patients without real treatment options today. We look forward to working with Jean-Guillaume and his team to transform Mablink into a global ADC player.” Valérie Calenda, the Managing Partner of Mérieux Equity Partners, says, “Merieux Equity Partners was attracted by the project at its inception in 2019 and decided to support it through its industrial accelerator M2Care before advising UI Investment and Pertinence Invest 2 to participate in the seed round. Since then, the quality of the team and progress reinforced our conviction that this platform can bring millions of patients safer and more potent ADCs thanks to an improved therapeutic window. As a result, we are delighted to continue supporting MabLink by co-leading this Series A financing with our venture fund OMX Europe.” “After a €4M Seed funding a year ago, Mablink enters a new era. We are particularly proud of the success of this Series A funding, which will increase exponentially the capacities and investments of the company in research and development, the consolidation of its pipeline, as well as the hiring of seasoned profiles,” says Florian Denis, Investment Director at Elaia, on behalf of the Mablink’s historic investors.

Elaia Partners Investments

158 Investments

Elaia Partners has made 158 investments. Their latest investment was in Giskard as part of their Seed VC on December 12, 2022.

CBI Logo

Elaia Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

12/15/2022

Seed VC

Giskard

$1.6M

Yes

1

12/1/2022

Seed VC

Arsen

$2.65M

Yes

1

11/18/2022

Seed VC - II

Spectral

$2.1M

No

1

11/10/2022

Series A

Subscribe to see more

$99M

Subscribe to see more

10

10/25/2022

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/15/2022

12/1/2022

11/18/2022

11/10/2022

10/25/2022

Round

Seed VC

Seed VC

Seed VC - II

Series A

Series A

Company

Giskard

Arsen

Spectral

Subscribe to see more

Subscribe to see more

Amount

$1.6M

$2.65M

$2.1M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

1

1

10

10

Elaia Partners Portfolio Exits

33 Portfolio Exits

Elaia Partners has 33 portfolio exits. Their latest portfolio exit was UWINLOC on January 04, 2023.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

1/4/2023

Acquired

$99M

1

10/4/2022

Corporate Majority

$99M

7

9/7/2022

Acquired

$99M

19

7/12/2022

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

7/4/2022

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/4/2023

10/4/2022

9/7/2022

7/12/2022

7/4/2022

Exit

Acquired

Corporate Majority

Acquired

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

1

7

19

10

10

Elaia Partners Fund History

5 Fund Histories

Elaia Partners has 5 funds, including Elaia Alpha II.

Closing Date

Fund

Fund Type

Status

Amount

Sources

7/11/2022

Elaia Alpha II

$77.29M

5/23/2019

PSL Innovation Fund

Subscribe to see more

Subscribe to see more

$99M

10

5/3/2017

Elaia Delta Fund

Subscribe to see more

Subscribe to see more

$99M

10

10/31/2012

ELAIA Alpha

Subscribe to see more

Subscribe to see more

$99M

10

12/31/2004

ELAIA Ventures

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

7/11/2022

5/23/2019

5/3/2017

10/31/2012

12/31/2004

Fund

Elaia Alpha II

PSL Innovation Fund

Elaia Delta Fund

ELAIA Alpha

ELAIA Ventures

Fund Type

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$77.29M

$99M

$99M

$99M

$99M

Sources

10

10

10

10

Elaia Partners Partners & Customers

1 Partners and customers

Elaia Partners has 1 strategic partners and customers. Elaia Partners recently partnered with IT-Translation on November 11, 2017.

Date

Type

Business Partner

Country

News Snippet

Sources

11/16/2017

Partner

France

IT-TRANSLATION and Elaia Partners combine their talents for the future – Elaia Partners

This partnership between Elaia Partners and IT-Translation is a natural evolution from previous colaborations between the teams .

1

Date

11/16/2017

Type

Partner

Business Partner

Country

France

News Snippet

IT-TRANSLATION and Elaia Partners combine their talents for the future – Elaia Partners

This partnership between Elaia Partners and IT-Translation is a natural evolution from previous colaborations between the teams .

Sources

1

Elaia Partners Service Providers

1 Service Provider

Elaia Partners has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Accounting Firm

General Counsel

Service Provider

Associated Rounds

Provider Type

Accounting Firm

Service Type

General Counsel

Partnership data by VentureSource

Elaia Partners Team

1 Team Member

Elaia Partners has 1 team member, including former Founder, Maryline Kulawik.

Name

Work History

Title

Status

Maryline Kulawik

Galileo Partners, and BNP Paribas

Founder

Former

Name

Maryline Kulawik

Work History

Galileo Partners, and BNP Paribas

Title

Founder

Status

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.